Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report
Yanmei Peng,1 Huijuan Cui,2 Zhe Liu,3 Daiwei Liu,1 Fan Liu,1 Yazhong Song,1 Hua Duan,1 Yuqin Qiu,1 Qiang Li1 1Department of China-Japan Friendship Hospital, Beijing University of Chinese Medicine, 2Department of Oncology, China-Japan Friendship Hospital, Chaoyang, 3Department of Oncology, Beijing C...
Main Authors: | Peng Y, Cui H, Liu Z, Liu D, Liu F, Song Y, Duan H, Qiu Y, Li Q |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-04-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/apatinib-to-combat-egfr-tki-resistance-in-an-advanced-non-small-cell-l-peer-reviewed-article-OTT |
Similar Items
-
Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
by: Xin Li, et al.
Published: (2020-03-01) -
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
by: Fang S, et al.
Published: (2017-01-01) -
How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01) -
Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
by: Guohui Liu, et al.
Published: (2019-10-01) -
Prevention of recurrent deep-vein thrombosis
by: Andrew N Nicolaides
Published: (2019-01-01)